Biocon Ltd — earnings calls

Biocon reported 10% year-on-year growth in group operating revenue for Q1 FY27, with biopharmaceuticals growing 17% while services revenue declined 16% due to lower offtake from a key biologics client. EBITDA stood at INR902 crores at a 21% margin, and reported net profit before exceptionals rose 245% year-on-year to INR145 crores. Management discussed segment performance across biosimilars, generics and Syngene, and addressed questions on profitability drivers, working capital, debt, US tariff risk, and the Bicara stake.

Biocon reported Q4 FY26 group operating revenue growth of 10% year-on-year excluding the prior-year lenalidomide bonus, with biosimilars growing 12%, generics excluding lenalidomide growing 13%, and CRDMO growing 2%. EBITDA came in at Rs 1,073 crore with a 23% margin, up 29% year-on-year on an adjusted basis, and reported net profit before exceptionals was Rs 179 crore. Management described completion of the Biocon Biologics minority buyout and integration of the biosimilars and generics businesses, and said interest cost savings from refinancing have begun accruing with full annualized benefit expected from FY27.